Human Albumin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing surgical procedures, widespread use in plasma volume replacement, rising burn and trauma cases, established safety profile of plasma-derived albumin, growth in dialysis patient population.

The growth in the forecast period can be attributed to expansion of critical care infrastructure, rising liver disease prevalence, growing demand for recombinant albumin, increased pharmaceutical formulation usage, improving plasma collection systems. Major trends in the forecast period include rising demand in critical care settings, expansion of albumin use in liver disorders, growing adoption in dialysis and surgery, shift toward recombinant albumin products, increasing role in drug formulation.

The rising incidence of chronic disorders is expected to drive the growth of the human albumin market. Chronic disorders, or chronic diseases, are long-term conditions that require ongoing medical management. The increase in chronic disorders is largely driven by factors such as aging populations, sedentary lifestyles, poor dietary habits, and increasing stress levels. Human albumin is commonly used in chronic kidney disease to manage hypoalbuminemia and maintain oncotic pressure, improving fluid balance and reducing complications. For example, in June 2023, Kidney Research UK, a UK-based charity, reported that approximately 7.2 million people in the UK are affected by chronic kidney disease, with 3.25 million individuals in severe stages and an additional 3.9 million in early, often undiagnosed stages. It is projected that by 2033, the chronic kidney disease population in the UK will reach 7.61 million. This rising incidence of chronic disorders is expected to fuel the growth of the human albumin market.

A key trend in the human albumin market is the focus on obtaining drug approval from regulatory authorities to gain a competitive edge. Securing drug approval ensures that a medication is safe, effective, and of high quality, which builds confidence among healthcare providers and patients, while allowing the product to be marketed and sold legally. For instance, in June 2023, Kedrion Biopharma Inc., an Italy-based biotechnology pharmaceutical company, announced the approval of Bio Products Laboratory's (BPL) human albumin product by China's National Institutes for Food and Drug Control (NIFDC), marking a significant milestone as the first BPL product approved for the Chinese market. This approval allows regular shipments to China, the largest market for human albumin.

In June 2024, Dyadic International, a US-based biotechnology company, formed a partnership with Proliant Health and Biologicals to commercialize animal-free recombinant human serum albumin products. This collaboration leverages Dyadic’s protein production technology and Proliant Health’s established market presence to target the growing $6 billion serum albumin market.

Major companies operating in the human albumin market are Takeda Biopharmaceuticals Private Ltd., Merck KGaA, Baxter International Inc., CSL Behring, Grifols SA, Octapharma AG, Sanquin Plasma Products BV, Taibang Biologic Group, Bovogen Biologicals Pty Ltd., Akron Biotech.

North America was the largest region in the human albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human albumin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the human albumin market by increasing costs for plasma collection materials, fractionation equipment, and cold-chain logistics. These cost pressures are most evident in hospital and critical care segments across North America and Europe that rely heavily on imported plasma-derived products. Supply chain constraints have affected availability for therapeutic and surgical applications. At the same time, tariffs are encouraging regional plasma fractionation facilities and recombinant albumin production, strengthening long-term supply resilience.

The human albumin market research report is one of a series of new reports that provides human albumin market statistics, including human albumin industry global market size, regional shares, competitors with a human albumin market share, detailed human albumin market segments, market trends and opportunities, and any further data you may need to thrive in the human albumin industry. This human albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human albumin is a naturally occurring protein found in plasma that plays a vital role in maintaining oncotic pressure and facilitating the transport of hormones, enzymes, drugs, and other substances in the blood. In medical therapy, human albumin is administered as an intravenous solution derived from pooled human plasma to treat conditions such as hypovolemia, hypoalbuminemia, burns, and acute respiratory distress syndrome (ARDS). It is also used during surgeries, including liver transplants and dialysis, to restore blood volume and stabilize circulation. Its ability to bind and carry various molecules makes it a crucial component in medical treatments, particularly for fluid replacement and shock management.

The main types of human albumin products include human serum albumin, recombinant albumin, and bovine serum albumin. Human serum albumin, a protein found in human blood plasma, is essential for maintaining osmotic pressure and transporting molecules such as hormones and drugs. Human albumin is used to produce human serum albumin products to ensure compatibility and support physiological functions in therapeutic applications. It is commonly used for treating hypovolemia, hypoalbuminemia, burns, shock, liver diseases, neonatal conditions, and in surgical and critical care settings. Additionally, human albumin is used in therapeutics, drug formulations, vaccines, media components, and other applications. The primary end users of human albumin products include hospitals and clinics, the pharmaceutical and biotechnology industries, and research institutes.

The human albumin market consists of sales of albumin solutions, albumin for plasma exchange, albumin for cell culture, and albumin for surgical applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.